Table 1.
Clinicopathological characteristics of the patients in our study.
| Variables | Normal | Breast Cancer | Benign | |||||
|---|---|---|---|---|---|---|---|---|
| Premenopausal (N = 62) | menopausal (N = 70) | Premenopausal (N = 62) | menopausal (N = 70) | Premenopausal (N = 62) | menopausal (N = 70) | |||
| Age, median (range) | 42(25-54) | 57(47-79) | 41(25-51) | 57(47-79) | 41(27-51) | 57(48-75) | ||
| Family history of breast cancer | 2 | 3 | 4 | 5 | 2 | 4 | ||
| HRT history | 0 | 0 | 0 | 0 | 0 | 0 | ||
| menstrual cycle | ||||||||
| week1 | 13 | NA | 13 | NA | 13 | NA | ||
| Week2 | 16 | NA | 16 | NA | 16 | NA | ||
| Week3 | 15 | NA | 15 | NA | 15 | NA | ||
| Week4 | 18 | NA | 18 | NA | 18 | NA | ||
| T stage | ||||||||
| T1 | NA | NA | 23 | 25 | NA | NA | ||
| T2 | NA | NA | 31 | 40 | NA | NA | ||
| T3 | NA | NA | 8 | 5 | NA | NA | ||
| N stage | ||||||||
| N0 | NA | NA | 34 | 51 | NA | NA | ||
| N1 | NA | NA | 24 | 16 | NA | NA | ||
| N2 | NA | NA | 4 | 3 | NA | NA | ||
| M stage | ||||||||
| M0 | NA | NA | 62 | 70 | NA | NA | ||
| M1 | NA | NA | 0 | 0 | NA | NA | ||
| Type | ||||||||
| luminal A | NA | NA | 5 | 5 | NA | NA | ||
| luminal B | NA | NA | 35 | 39 | NA | NA | ||
| HER-2 enriched | NA | NA | 19 | 21 | NA | NA | ||
| Triple negative | NA | NA | 3 | 5 | NA | NA | ||
NA, not applicable; HER-2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy.